NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Issues Corporate Update; Reports First Patients Dosed in Phase II OPTION Study
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, this morning issued a clinical development and strategic corporate update. In the update, the company reports that the first patients have been dosed in its phase II OPTION study to investigate MS1819-SD in cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). Planned enrollment of the study is anticipated to include approximately 30 CF patients, with initial top line data results expected in mid-2019. The OPTION study is presently enrolling patients at five sites in the U.S. and anticipates up to six additional…







